Shuffler News
Parkinsons and Dopamine Agonists, a story !
The words of someone who has been to hell and back and still climbing out of it.
“Agonists are like your best friend acting nice, but in the bigger picture they have an alterior motive far more sinister than any benefit that the friendship could ever provide.
For most it works, but my experience was stomach churningly horrendous, with life long repucussions of the highest order, loss of business, reputation, family houses, economic and social supports.
Structured social and medical supports, as well as paitent suitability given patient personailty and lifestyle, are required that extend way beyond what the medical profession currently offers .
These supports need to look for and continually monitor for the hidden signals, behaviour changes, reclusiveness, adverse risk taking, clouded judgement, as the participant can very easily deliberately hide the obvious signs of compulsive behaviour, which may seem trivial to those looking in, but will rock the foundations for the person who sought the benefit, ripping their insides with decay and leaving a shell of a human with nothing left inside.”
There is a moral duty of care that isn’t being acknowledged, and those affected are too proud to publicly admit that they fell prey to the fiery forks of the devil disguised.
This could never happen to me, I won’t be judged by my friends so I’ll keep it to myself”
Stories from Agonist Survivors
Parkinsons: Dopamine Agonists. Dangers !
Facing the Beast and Being Honest About My Suffering
Even after years of practicing the Parkinson’s disease self-management program I initiated and developed, which I call “TBM,” I still experience suffering in the form of intense pain, brain fog, and emotionally turbulent days. Still,
MJFF Awards 2 Bachmann-Strauss Fellowships in Dystonia Research
A new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the movement disorder known as dystonia. Launched by the Michael J. Fox Foundation for Parkinson’s Research (MJFF),
Regular, Sustained Physical Activity May Help Slow Disease Progression
Regular and sustained physical activity, including daily pursuits such as walking or gardening, may help slow the progression of Parkinson’s in people with early-stage disease, a long-term follow-up study suggests. Patients who exercised regularly over five
Tapering Ropinirole Caused Me Some Scary Side Effects
I’m back! Not just figuratively, but also literally. I recently took some time off to get my health in check. I was in the process of changing medications, and my neurologist had warned me that
5 Lessons I’ve Learned on My Parkinson’s Journey
If you’re a Parkinson’s veteran, what would you tell a rookie? If you’re a rookie, what Parkinson’s lessons would you like to learn? I was diagnosed in late 2014 with young-onset Parkinson’s disease at the
Dosing Starts in Canada in Trial of DA01 for Advanced Parkinson’s
A first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson’s disease by BlueRock Therapeutics. The therapy consists of surgically injecting neurons (nerve cells) that
FDA Allows Yumanity to Test Single Doses of YTX-7739
The U.S. Food and Drug Administration (FDA) has issued a partial clinical hold in response to an application by Yumanity Therapeutics requesting permission to begin clinical testing in the U.S. of YTX-7739 for Parkinson’s disease.
Identifying Our Secret Superpowers
It’s a crisp January morning when my best friend and I ask each other about our superpowers. He tells me he’s as fast as lightning, which is funny because he’s a semi-pro ultra runner. I
Skin-deep Symptoms of Parkinson’s Disease
Here in Arizona, dry, flaky, and itchy skin is a common problem because we get 335 days of sunshine. But my sister Bev, who has stage 3 Parkinson’s disease, experiences the same problems with her
Alpha-synuclein Plays ‘Critical’ Role in Immune Responses to Inflammation
The protein alpha-synuclein, which has a well-established role in the development of Parkinson’s disease, is necessary for the body to mount a normal immune response against infections. “This study provides further evidence that αS [alpha-synuclein],
Posts from the author
Shufflernews
Parkinsons
Subscribe
Phone
0490 33 22 68
shuffles@shufflenews.com